Drug intelligence / Profile preview

PD-DP-017

Development stage: Preclinical
Lead developer: Chengdu Peide Biopharmaceutical
Modality: Small Molecules

Overview

PD-DP-017 is a small molecule therapeutic candidate being developed by Chengdu Peide Biopharmaceutical (PDBio) for the treatment of pain, specifically post-operative pain. As of 2024, the program is in the lead optimization or early pre-clinical candidate (PCC) stage. The developer has projected an Investigational New Drug (IND) application for the asset in 2026. While the specific biological target and mechanism of action have not been publicly disclosed, the drug is part of a broader effort by PDBio to develop novel analgesics for acute pain management.

Beyond the preview

Go deeper on PD-DP-017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-DP-017.

Explore the full profile